Tuberculin conversion following BCG vaccination in preterm infants

Area of Science:

• Immunology
• Pediatrics
• Vaccinology

Background:

• Bacillus Calmette-Guérin (BCG) vaccination is crucial for preventing tuberculosis (TB) in infants.
• Optimal timing for BCG vaccination in preterm infants remains a subject of investigation.
• Assessing tuberculin conversion rates is a key indicator of BCG vaccine efficacy.

Purpose of the Study:

• To evaluate the effectiveness of BCG vaccination at birth in preterm appropriate-for-gestational-age (AGA) infants.
• To compare tuberculin conversion rates between preterm infants vaccinated at birth and those vaccinated later.
• To compare tuberculin conversion rates between preterm and term AGA infants vaccinated at birth.

Main Methods:

• Three groups of infants were studied: preterm AGA (vaccinated at birth), term AGA (vaccinated at birth), and preterm AGA (vaccinated around their estimated due date).
• BCG vaccination was administered to all groups.
• Tuberculin conversion rates were assessed post-vaccination.

Main Results:

• Tuberculin conversion rates were 83% in preterm infants vaccinated at birth (Group I), 93% in term infants vaccinated at birth (Group II), and 88% in preterm infants vaccinated around their due date (Group III).
• The observed differences in tuberculin conversion rates among the three groups were not statistically significant (p > 0.5).

Conclusions:

• BCG vaccination at birth is effective in preterm AGA infants born between 32-36 weeks of gestation.
• The timing of BCG vaccination does not significantly impact tuberculin conversion rates in preterm AGA infants.
• These findings support the practice of early BCG immunization for eligible preterm infants.